Sub-theme: Pharmaceutical therapies
Genmab is a drug therapy company focused on differentiated antibody products in oncology. The company has developed industry-leading antibody discovery technologies which have led to a strong pipeline of potential best-in-class and first-in-class therapies. Through partnerships Genmab has successfully developed several products, including treatments for multiple myeloma, cervical cancer, multiple sclerosis and thyroid eye disease.
Impact Score: 57%
Genmab’s therapies are typically used to treat diseases with very poor outcomes – survival rates are measured in months. Their largest drug has shown significant improvements in progression free survival and remission rates 6x better than the existing treatment regimen. Clinical studies of pipeline drugs also show promising early data.
Fundamental Quality: 72%
Genmab’s antibody platform technology is industry-leading. To date it has operated under a partnership model which has allowed it to develop a strong pipeline while generating strong margins and building up a net cash balance sheet. The next stage of growth will see Genmab take a greater share of the economics by participating in the commercialisation stage.
(per £1m invested)
- Auditor independence
- Executive remuneration
- Net Zero Carbon target
- Side-effects from pharmaceuticals
- Product pricing restricts access for poor communities
- Plastic waste from packaging
- Animal testing of pharmaceuticals
